Indications
Prevention of invasive fungal infections with reduced immunity and an increased risk of developing such infections, for example, in hematological patients with prolonged neutropenia due to chemotherapy, as well as in recipients of hematopoietic stem cell transplants receiving high doses of immunosuppressants.
Treatment of invasive fungal infections:
invasive candidiasis or candidiasis of the esophagus, refractory to amphotericin b, and Itraconazole or fluconazole, or intolerance to these drugs;
invasive aspergillosis refractory to amphotericin b or Itraconazole, or intolerance to these drugs;
— zygomycosis (mucormycosis), cryptococcosis refractory to other antifungal medicines, or with intolerance;
— Fusarium refractory to amphotericin b In, or with its intolerance;
— chronomics and mycetoma refractory to Itraconazole, or if it is intolerance;
— the coccidioidomycosis, refractory to amphotericin b, and Itraconazole or fluconazole, or intolerance to these drugs.
Refractoriness is considered to be the progression of infection or the lack of improvement in the patient’s condition after treatment for 7 days (for candidemia – for 3 days, for esophageal candidiasis – for 14 days, for other forms of invasive candidiasis-7 days).
Treatment of oropharyngeal candidiasis is first-line therapy in patients with severe disease or with reduced immunity, who are not expected to have a significant effect from the use of topical drugs.
Reviews
There are no reviews yet